At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 211 enrolled
Drug / intervention
Chloroprocaine HCl 2% +1 moredrug
Likely dose
Chloroprocaine HCl 2% 20mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery
In Brief
A Phase 3 clinical trial evaluating Chloroprocaine HCl 2% and Ropivacaine 0.75% for Axillary Nerve Block. Completed, enrolled 211 participants across 1 site.
Detailed Summary
The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without any supplementation in the first 45 min.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAxillary Nerve Block
CountriesSwitzerland
CollaboratorsCross S.A.
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartApr 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedMar 11, 2015
Enrollment StartApr 1, 2015
Primary CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.3 years ago
Interventions
Chloroprocaine HCl 2%drug
Single Administration (20mL) by Axillary Nerve Route
Ropivacaine 0.75%drug
Single Administration (20mL) by Axillary Nerve Route